J&J Obtains Approval By Crucell's Boards For Proposed Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition would add vaccines to J&J's diverse empire, and make it the sixth-largest player in that space.
You may also be interested in...
J&J's Bid For Crucell Hits Speed Bump With Shipment Suspension At Korean Vaccine Plant
Johnson & Johnson's acquisition offer for Crucell appears to be on track despite news that the Dutch biotech firm suspended all shipments of hepatitis B vaccine Hepavax-Gene and childhood pediatric vaccine Quinvaxem due to issues at its Korean unit Berna Biotech Korea.
J&J's Bid For Crucell Hits Speed Bump With Shipment Suspension At Korean Vaccine Plant
The acquisition appears to be on track despite news that the Dutch biotech suspended all shipments of hepatitis B vaccine Hepavax-Gene and childhood pediatric vaccine Quinvaxem due to issues at its Korean unit.
J&J's Bid For Crucell Hits Speed Bump With Shipment Suspension At Korean Vaccine Plant
The acquisition appears to be on track despite news that the Dutch biotech suspended all shipments of hepatitis B vaccine Hepavax-Gene and childhood pediatric vaccine Quinvaxem due to issues at its Korean unit.